IKT - צמיחת הכנסות ב-12 חודשים נגררים inhibikase.com

Inhibikase Therapeutics leverages the RAMP platform to develop exclusive therapies for neurodegenerative pathologies. However, geopolitical tensions and sanctions are hindering the international certification of new drugs. Year-over-year revenue dynamics over the last 12 months illustrate the impact of these factors, where -99.80 shows the value of this parameter. Simultaneously, the robotization of laboratory screening is accelerating the search for effective compounds to combat brain diseases.
Inhibikase Pharma (IKT) - פילוחי מדדים ודוחות פיננסיים

Investors view Inhibikase Therapeutics (IKT) as a high-risk asset whose value depends on FDA approval of drugs for Parkinson's disease. This trend in year-over-year sales over a 12-month period measures TTM revenue growth rates, neutralizing seasonal fluctuations and inflationary noise to assess the real operational dynamics of a biotech business protected by R&D patents.